Studi In Silico Senyawa Daun Salam Sebagai Antidiabetes Melalui Mekanisme Inhibitor SGLT-2
Abstract
Purpose: This study aims to investigate the potential of bioactive compounds from Indonesian bay leaf (Syzygium polyanthum) as Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors for the treatment of diabetes mellitus using an in silico approach.
Methodology/approach: The methodology included identifying bioactive compounds from bay leaf, preparing the SGLT-2 protein structure, molecular docking using Molegro Virtual Docker, molecular dynamics simulations with YASARA Dynamics, and data analysis focusing on rerank scores and RMSD (Root Mean Square Deviation) values.
Result/findings: The in silico study revealed that several bioactive compounds in bay leaf, such as flavonoids and phenolic acids, exhibit a strong affinity and specific interaction with SGLT-2, which yielded more negative rerank scores than empagliflozin, indicating stronger binding affinity. Molecular dynamics simulations confirmed the stability of ligand-protein binding, particularly for 3,4-dicaffeoylquinic acid.
Conclusions: Bay leaf compounds like flavonoids and phenolic acids showed strong binding to SGLT-2, with better rerank scores than empagliflozin. Molecular dynamics confirmed stable interactions, especially for 3,4-dicaffeoylquinic acid.
Limitations: This study is limited by variations in dosage and treatment duration in existing research, the use of animal models that do not fully replicate human type 2 diabetes, and the need for further in vitro and in vivo validation.
Contribution: This study…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.